Industry Insights: MedComms 2 October
Here we cover three hot topics in publishing that are shaping the industry dialogue. We focus on BioGPT: a generative AI model that generates fluent descriptions for biomedical terms, why there is a call to reform the current scholarly publishing model, and using the patient voice in publishing. As generative AI models like BioGPT and […]
Industry Insights: Healthcare 25 September
This week our industry insights look at news highlighting the importance of full disclosure in the promotion of medicines, EU recommendation for the approval of an antibody-drug for the treatment of NSCLC, and a popular oral decongestant that could be removed from the US market. Novartis has been found to have seriously breached the ABPI […]
Industry Insights: MedComms 18 September
With the ongoing pressure in the academic world to publish, the term ‘Publish or Perish’ is well known. Here we cover three important and related topics in the industry. We look at the use of embellished language (hyperbolic adjectives) in scientific writing, and publishing in predatory as well as open access (OA) journals. In recent […]
Industry Insights: Healthcare 11 September
This week, our industry news insights looks at an announcement of a new phase III trial for non-small cell lung cancer, artificial intelligence (AI) for breast cancer detection, and dramatic increases in cancer rates for under-50s. Taiho Oncology and Cullian Oncology have announced the phase III trial of zipalertinib in EGFR exon 20 insertion mutation […]
Industry Insights: MedComms 4th of September
Here we examine three hot topics in medical writing that are shaping the industry dialogue. We take a look at the impact of retracted scientific articles, the advantages of using artificial intelligence (AI) in text creation, and the ban by Nature on the use of AI-generated visual content in its journals. There is increasing concern […]
Industry insights: Healthcare 28th of August
Here are three briefly summarised articles to help keep you informed of the latest developments in the industry. This week take a look at new US Government funding into vaccines and therapies for COVID and FDA clearance for new AI technology to help spot lung nodules. We also explore the impact of Keytruda (pembrolizumab) in […]
Industry Insights: Healthcare 14 August
Here are three briefly summarised articles to help keep you informed of the latest developments in the industry. This week our industry insights look at news highlighting how artificial intelligence (AI) could be used for cancers of unknown primary origin, further findings from a Novo Nordisk’s Wegovy trial, and a new novel oral treatment for […]
Industry insights: Healthcare 1st of August
Obesity and rheumatological conditions are an area of Elion’s expertise. This week our industry news insights look at the correlation between obesity and psoriasis, findings from a trial of a promising treatment for Alzheimer’s, and the initiation of Phase III study involving Merck’s Keytruda. It is well established that obesity is a risk factor for […]
Industry insights: Healthcare 3rd of July
Oncology, particularly lung and breast cancer, is an area of Elion’s expertise. This week we have found news highlighting the progress made in small cell lung cancer, identification of a new subtype of depression, and a promising trend in breast cancer survival rates. Small cell lung cancer (SCLC) accounts for 13-15% of all lung cancer […]
Industry insights: Healthcare 26th of June
Mental health is one of Elion’s areas of expertise. This week we’ve found industry news highlighting promising therapies for Alzheimer’s and schizophrenia, as well as a caution about commenting on social media. Independent advisors to the FDA have unanimously agreed that Leqembi, an Alzheimer’s drug being developed by Eisai-Biogen, benefits patients. Leqembi is an amyloid beta-directed […]
Industry insights: Healthcare 18th June
These are three healthcare industry stories that caught our eye last week. There are some fascinating developments happening in the fields of obesity management and oncology, both of which are areas in which we currently work. Anti-obesity drug sales are predicted to hit $44B by 2030 Anti-obesity drugs have had increasing media attention, partly driven […]
